Mismatch repair (MMR) is important for repairing of nucleotide mismatches during DNA replication. Germline mutations in MMR genes are associated with hereditary non-polyposis colorectal cancer (HNPCC). Ovarian cancer occurs as part of the HNPCC phenotype, and so common variants in MMR genes are candidates for ovarian cancer susceptibility. We performed a large multicentre case-control study to investigate associations of common variations in MMR genes and ovarian cancer using a single nucleotide polymorphism (SNP) tagging approach. A total of 2570 controls and 1531 cases from three separate studies were genotyped for 44 tagging SNPs (stSNP) in seven MMR genes (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1 and PMS2). Genotype frequencies were marginally different between cases and controls for PMS2 rs7797466 (P 2df ¼ 0.046) with a 1.17-fold (95% CI 1.03-1.33) increase in risk for each 'a' allele carried (P-trend ¼ 0.013). Haplotype analysis of PMS2 also showed significant differences in frequencies between cases and controls (P 7df ¼ 0.005), with one haplotype accounting for most of the effect. There was also marginal evidence for a recessive protective effect with common homozygote as the baseline comparator for two SNPs-MSH6 rs3136245 (OR 0.67; 95% CI 0.46-0.98) and MSH3 rs6151662 (OR 0.28; 95% CI 0.08-0.91)-but the comparisons of genotype frequencies for these variants were not significant (P ¼ 0.10 and 0.054). In conclusion, it is unlikely that common variants in MLH1, MLH3, PMS1, MSH2, MSH3 and MSH6 contribute significantly to ovarian cancer susceptibility. The observed association of PMS2 rs7797466 with ovarian cancer warrants confirmation in an independent study.
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Introduction
Ovarian cancer is the sixth most common malignancy occurring in women and causes 125 000 deaths annually in women worldwide (1) . The aetiology of ovarian cancer is not fully understood-but family and twin studies suggest that inherited factors are an important cause (2) . The known ovarian cancer susceptibility genes, such as BRCA1 and BRCA2, explain <30% of the excess familial risk of ovarian cancer. It has been hypothesized that common, low to moderate penetrance alleles account for most of the remaining risk.
It is widely accepted that human neoplastic transformation including ovarian cancer is a multi-step process and involves the accumulation of genetic alterations. Mismatch repair (MMR) is one of the most important DNA repair processes. It is responsible for the repair of nucleotide mismatches during DNA replication and prevents the propagation of potentially harmful mutations in genes including those involved in cancer development (3) (4) (5) . Loss of MMR function leads to genetic instability, which can be identified as microsatellite instability (MSI) in tumours with deficient MMR. MSI has been identified in multiple different types of sporadic cancer, including prostate (6) , pancreatic (7) , gastric cancers (8) and ovarian cancer (9) . Germline mutations in MMR genes are also responsible for the inherited susceptibility syndrome, hereditary non-polyposis colorectal cancer (HNPCC), which is typically characterized by cancer of the colorectum, but also cancers in the upper gastrointestinal tract, the endometrium and ovary (10) . To date all but MSH3 have been shown to be associated with an inherited predisposition to cancer. MMR gene mutation carriers have nearly a 10-fold rise in risk of ovarian cancer in female (3) . Furthermore, hypermethylation of the MLH1 promoter region has been found in MSI cancers of ovary (11) and endometrium (12) that do not contain germline MLH1 mutations. Geisler et al. (13) reported that 16.8% of ovarian carcinoma cases have defects of the DNA MMR system. A recent study demonstrated that MMR deficiencies was involved in the development and/or progression of a proportion of epithelial ovarian cancers through the accumulation of genetic alterations (14) .
The seven known genes in the MMR pathways-MSH2, MSH3, MSH6, MLH1, MLH3, PMS1 and PMS2-are located on five different chromosomes. MSH2, MSH6 and PMS1 are on chromosome 2, MLH1 is on chromosome 3, MSH3 is on chromosome 5, PMS2 is on chromosome 7 and MLH3 is on chromosome 14. The coding and non-coding content of these genes ranges from $24 kb (MSH6) to $222 kb (MSH3). The protein products have a variety of functions in the recognition and repair of DNA mismatches. MSH2/MSH6 (MutSa) and MSH2/MSH3 (MutSb) form heterodimers that recognize and bind to the mismatch region (15) ; MutL (MLH1/PMS1 or MLH1/PMS2) is involved with mismatch strand excision and subsequent repair (15) . Gene defects in MSH2 result in the loss of both MutSa and MutSb and complete inactivation of MMR function. MSH6 and MSH3 have some overlap in their function-consequently, inactivation of either of these genes individually has a lesser impact (16) . MLH3 was only recently identified and found to be associated with mammalian MSI (17) .
Most high penetrance MMR mutations lead to loss of protein function and genetic instability and ultimately predispose to cancer. However, it is also possible that there are several common polymorphisms in these genes that may be associated with variation in cancer risk. Recently, the rare MLH1 D132H variant was found to be associated with susceptibility to colorectal cancer (18) and polymorphisms in PMS2 were associated with HNPCC (19) . Because ovarian cancer occurs as part of the HNPCC phenotype, we hypothesize that common MMR gene variants may lead to variation in ovarian cancer risk. The purpose of this study was to investigate whether any associations exist between disease risk and MMR polymorphic variation in a large, multicentre ovarian cancer case-control study.
Materials and methods

Study subjects
The cases and controls used for this study were from three different casecontrol studies: the SEARCH study from the UK, the Malignant Ovarian Cancer (MALOVA) study from Denmark and the Family Registry for Ovarian Cancer (FROC) study from the USA (Table I) .
The SEARCH ovarian cancer study is an ongoing, population-based ovarian cancer case-control study covering the regions served by the East Anglia and West Midlands cancer registries in the UK. All patients diagnosed in East Anglia with invasive epithelial ovarian cancer under the age of 70 years since 1991 and still alive in 1998 when recruitment started to take part (prevalent cases). Incident cases are those diagnosed <70 years since 1998 in East Anglia and since 2003 in the West Midlands. From 1991 to the end of 1997, 1181 women were registered in East Anglia of whom 767 had already died and the general practitioner refused permission to contact 166. Thus, we invited 248 women to take part, of whom 216 provided a blood sample (87% of those invited and 18% of all eligible diagnoses in the region). As the study is ongoing, the following data are based on registrations in East Anglia from 1998 to 2004 for which recruitment has been completed. In this period 1453 women were registered of whom 334 had died by the time of registration and the general practitioner refused permission to contact 531 (reason unknown). Of 588 women invited to take part 476 provided a blood sample (81% of those invited and 33% of all eligible diagnoses). To date we have invited 1750 women to participate of whom 1157 have provided a blood sample-the first 732 cases were available for this analysis. Female controls (n ¼ 855) have been randomly selected from the EPIC-Norfolk component of the European Prospective Investigation of Cancer (EPIC), a prospective study of diet and cancer being carried out in East Anglia. The EPIC Norfolk cohort comprises 25 000 individuals resident in Norfolk, aged 35-74 years at first interview in 1993. Blood for DNA extraction was collected during the second health check in 1998-2000 (84%). The ethnic background of cases and controls is similar, with over 98% being white Europeans. Participants are asked to provide written consent, to complete an epidemiological questionnaire and to provide a 20 ml whole blood sample. The study is approved by the Eastern Multi-centre Research Ethics Committee. DNA was extracted from blood samples by Whatman International Ltd (Ely, UK) using a chloroform-phenol method.
The MALOVA study is a population-based, Danish case-control study of ovarian cancer. Eligible cases were women aged 30-80 years, who were diagnosed with an ovarian tumour from December 1994 to May 1999. The study included 18 different hospitals from the municipalities of Copenhagen and Frederiksberg as well as the counties of Copenhagen, Frederiksborg, Roskilde, Western Sealand, Storstrøm, Funen, Southern Jutland and Northern Jutland. By the end of the study period, a total of 959 ovarian cancer patients were identified in this study area. Of these, 53 patients were considered too ill to participate, 45 women died before being contacted. Thus, 861 were invited to take part of whom 652 (76%) provided a blood sample. Controls were drawn from the general female population within the study area (aged 30-80 years) selected at random using the computerized Central Population Register. Of 3137 eligible controls 2116 (67.5%) enrolled-1564 completed a personal interview and 552 completed a telephone interview. Samples from 472 cases and 1286 controls were available for this study. DNA was extracted from blood using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA). This study has been approved by the scientific ethical committee in the study area, KF01-384/95 and all subject provided written consent.
The USA subjects were ascertained from six counties in Northern California as part of the FROC. Patients with epithelial ovarian cancer diagnosed between March 1, 1997 and July 31, 2001 were identified through the Greater Bay Area Cancer Registry operated by the Northern California Cancer Center as part of the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute. Rapid case ascertainment was used to identify cases within 1 month of diagnosis. Eligible patients were those diagnosed with invasive or low malignant potential epithelial ovarian cancer at ages 20-64 years who resided in six Bay Area counties (Alameda, Contra Costa, Marin, San Francisco, San Mateo or Santa Clara). Of the 915 eligible patients, 24 were not contacted because their physicians refused permission, 209 refused to participate, had died or could not be located, and 682 (75%) were interviewed. Of these, 579 (85% of those interviewed and 63% of total) provided a blood or mouthwash sample for DNA extraction.
Control women were identified through random-digit dial and were frequency-matched to cases on race/ethnicity and 5-year age group. Of 1041 controls randomly selected into the study, 746 (72%) completed the telephone screening interview, 162 (16%) refused to participate and 133 (13%) could not be located. Of 689 control women who met the eligibility criteria (i.e. no prior history of breast or ovarian cancer), 626 (91%) completed the detailed family history and epidemiology questionnaires and 585 (85%) provided a blood or mouthwash sample. In addition, 244 first degree relatives of cases without ovarian or breast cancer were recruited for the study.
Samples of heparinized, peripheral blood or buccal mouthwash rinse were shipped to Roswell Park Cancer Institute, Buffalo, NY. Genomic DNA was isolated from leucocytes of peripheral blood using the Puregene Kit (Gentra Systems, Minneapolis, MN). Genomic DNA was also isolated from exfoliated cells in buccal mouthwash rinses as described previously (20) . Research was conducted with protocols approved by the Institutional Review Boards of Stanford University School of Medicine and Roswell Park Cancer Institute. This analysis is restricted to the 327 white and white non-Hispanic cases with invasive epithelial ovarian cancer, and the 429 age-and race/ ethnicity-matched controls who had not undergone bilateral oophorectomy. The relative controls were not included in this analysis.
Tag SNP selection
We started this project before detailed information on common genetic variation in MMR genes was available. Initially we selected several common SNPs of varying frequencies from the dbSNP database (http://www.ncbi.nlm. nih.gov/SNP) and other public databases. Shortly after this, resequencing data from the NIEHS Environmental Genome Project (EGP) (http://egp.gs. washington.edu/) became available for MSH6 and PMS1. Resequencing enable us to carry out a more systematic selection of SNP tagging SNPs (stSNPs). The EGP has been resequencing candidate genes for cancer across panels of individuals representative of US ethnicities. The original The aim of the SNP tagging was to identify a set of stSNPs that efficiently tags all the known common variants (minor allele frequency (MAF) >0.05) and is likely to tag most of the unknown common variants in the gene. The best measure of the extent to which one SNP tags another SNP is the pairwise correlation coefficient (r p 2 ), since the loss in power incurred by using a maker SNP in place of the true causal SNP is directly related to this measure. Where a SNP is poorly correlated with any other single SNP, it may be efficiently tagged by a haplotype defined by multiple SNPs, thus reducing the number of tagging SNPs needed. The correlation between a multi-SNP haplotype and an individual SNP is r 2 s . We aimed to achieve a minimum correlation between each SNP and a haplotype of tagging SNPs (r s 2 ) to be 0.8. As tagging SNP selection based on r 2 s will be inefficient where there is excessive haplotype diversity, we divided the gene into haplotype blocks and selected the stSNPs for each block separately using the programme tagSNPs (21) . SNPs that were originally selected were forced in as stSNPs. If assay design failed for a selected stSNP the tagging selection was repeated with forced exclusion of the failed SNP in order to select an alternative (where possible). It is possible to use a variety of formal definitions of haplotype blocks; but we simply used the graphical representations of the pattern of linkage disequilibrium (LD) based on D 0 and selected blocks such that the common haplotypes in each block accounted for at least 80% of all haplotypes observed using the Haploview program (22) . The selection of stSNPs for each gene was performed as follows:
MLH3: Neither HapMap nor EGP data were available for this gene at the start of the project. Therefore, we genotyped two SNPs available for this gene as Assays-on-Demand from Applied Biosystems (http://www. appliedbiosystems.com). These two SNPs generate three haplotypes, which account for 99% of all the haplotypes. Subsequently, HapMap released data for 11 different SNPs. However, these SNPs are in very strong LD and again, there were only three common haplotypes explaining 98% of haplotype diversity. As the 11 SNPs could be tagged by just two SNPs (r p 2 > 0.93) it is highly likely that the two SNPs we have genotyped will have tagged the gene efficiently.
MSH2: Data for 26 common SNPs covering 82 kb were available in HapMap (21-06-2005 HapMap public release). There was a single LD block with common haplotypes accounting for 86% of all the haplotypes. Seven tagging SNPs were chosen; 21 out of 26 SNPs were tagged by r MSH6: EGP resequencing data covered 84% of the gene and identified 42 common SNPs. Three SNPs were poorly correlated with any others. After excluding these there were two LD blocks in which the common haplotypes accounted for 76 and 89% of all haplotypes. However, the presence of substantial LD between blocks allowed all SNPs to contribute to tagging outside its own block. Assay design failed for a total of nine SNPs that were initially selected as tags and ultimately there were six tagging SNPs in block 1 and one in block 2. The mean r 
MLH1: EGP resequencing data covered 30% of the gene and 15 common SNPs were identified. There was a single LD block in which common haplotypes comprised 95% of all the haplotypes. Four stSNPs were chosen. Thirteen SNPs were tagged by single marker with minimum r The number of common SNPs and number of tagging SNPs identified in each MMR gene are described in Table II .
Genotyping
All samples were genotyped using the Taqman 7900HT Sequence Detection System according to manufacturer's instructions. Each assay was carried out using 10 ng DNA in a 5 ml reaction using TaqMan universal PCR master mix (Applied Biosystems), forward and reverse primers and FAM and VIC labelled probes designed by Applied Biosystems (ABI Assay-by-design). Primer and probe sequences and assay conditions used for each polymorphism analysed are available from the corresponding author on request. All assays were carried out in 384-well arrays with 12 duplicate samples in each plate for quality control. Assays where genotypes in duplicated samples did not show >95% concordance were discarded and replaced with alternative assays with the same tagging properties. Genotypes were determined using Allelic Discrimination Sequence Detection Software (Applied Biosystems, Warrington, UK). DNA samples that did not give a clear genotype result at the first attempt were not repeated. Hence, there are variations in the number of samples successfully genotyped for each polymorphism.
Statistics
The three studies were treated as separate strata in the analyses. Deviations of the genotype frequencies in the controls from those expected under Hardy-Weinberg equilibrium (HWE) were assessed by c 2 -tests (1 d.f.). The primary tests of association were the univariate analyses between each tagging SNP and ovarian cancer. Genotype frequencies in cases and controls were compared for each study separately using c 2 -tests for heterogeneity (2 d.f.). The data were then pooled and genotype frequencies were compared in cases and controls using unconditional logistic regression with terms for genotype and study and an appropriate likelihood ratio test. We tested for heterogeneity between study strata by comparing logistic regression models with and without a genotype-stratum interaction term using likelihood ratio tests. Genotypic specific risks with the common homozygote as the baseline comparator were estimated as odds ratios (OR) with associated 95% confidence interval (95% CI) by unconditional logistic regression. We also tested for rare allele dose effect (assuming a multiplicative model) using c 2 -tests (1 d.f.) for each study separately and unconditional logistic regression for the pooled data.
In addition to the univariate analyses, we carried out global haplotype tests for each gene/haplotype block, because some SNPs were tagged by multimarker haplotypes. Haplotype frequencies and subject-specific expected haplotype indicators were calculated separately for each study using the programme TagSNPs, which implements an expectation-substitution approach to account for haplotype uncertainty given unphased genotype data (23) . Subjects missing >50% genotype data in each MMR gene were excluded from haplotype analysis. We considered haplotypes with >2% frequency in at least one study to be 'common'. Rare haplotypes were pooled. We used unconditional logistic regression to test the global null hypothesis of no association between haplotype frequency and ovarian cancer, by comparing a model with multiplicative effects for each common haplotype (treating the most common haplotype as the referent) to the intercept-only model. Haplotype specific odds ratios were also estimated with their associated confidence intervals.
Results
We have genotyped 42 SNPs in 7 MMR genes in three ovarian cancer case-control studies (Table III ). An additional two SNPs-MLH1 rs1799977 and MSH6 rs3136317-were genotyped for the SEARCH and FROC studies, but the genotype call rate for the MALOVA samples was unsatisfactory. Out of 130 genotype distributions in controls 9 distributions deviated from HWE (P < 0.05) compared with 7 expected by chance, but this occurred in only one of the studies for any given SNP apart from MSH3 rs10079641, which deviated from HWE in both SEARCH (P ¼ 0.001) and FROC (P ¼ 0.04). These findings are unlikely to be owing to genotyping errors because no SNP deviated from HWE in both cases and controls and the discrimination of genotypes for these assays was good. The genotype distributions and genotypic specific risks for each study are presented in Supplementary Table S1 . The genotype frequencies in controls were similar for all three study populations (P > 0.05), apart from five SNPs in MSH3 (rs6151662, rs40139, rs26779, rs2897298 and rs2112416; P < 0.05) (Supplementary Table S1 ). The observed genotype frequencies from the combined dataset are presented in Table III , which also shows the result of the test for heterogeneity of genotype frequencies (P-het) between cases and controls in combined data. The genotypic specific risks for the combined data and the result of the trend test for association are presented in Table IV . There was no difference in genotype frequency in ovarian cases and controls for 43 of SNPs tested. However, there was a marginally significant association for PMS2 rs7797466 (P ¼ 0.046) with a 1.17-fold (95% CI 1.03-1.3) increase in risk for each 'a' allele carried (P-trend ¼ 0.013). There was no evidence of heterogeneity between studies (P ¼ 0.10). There was some evidence for a recessive effect for two SNPs-rare allele homozygotes for MSH6 rs3136245 and MSH3 rs6151662 being at reduced risk of ovarian cancer [OR 95% CI 0.67 (0.46-0.97) and 0.28 (0.08-0.91), respectively]-but the comparisons of genotype frequencies for these variants were not significant (P ¼ 0.10 and 0.054). There was no evidence of heterogeneity between studies for rs3136245 (P ¼ 0.57) but with some evidence of heterogeneity between studies for rs6151662 (P ¼ 0.04).
The haplotype frequencies for each gene in cases and controls in combined analysis were estimated after stratification and the results for haplotype specific risks and association test are presented in Table V . No significant differences in haplotype frequencies were seen between cases and controls for MLH1, MLH3, PMS1, MSH2 and MSH3. However, for PMS2 the haplotype frequencies differed significantly (global test P ¼ 0.005). This was owing to the effect of a single haplotype comprising the rare allele of rs7797466 and the common allele of the other five SNPs [OR ¼ 1.51 95% CI (1.18-1.94)]. One MSH6 haplotype frequency was slightly different in cases and controls (P ¼ 0.04) and had reduced risk [OR ¼ 0.78; 95% CI (0.61-0.99)]; however, the global test is not significant (P 6df ¼ 0.31).
Discussion
To our knowledge, this is the first comprehensive study to systematically tag all the known common variants in the genes in the MMR pathway and to test the tag SNPs for association with ovarian cancer susceptibility. We found borderline evidence for an association of PMS2 rs7797466 (P-heterogeneity ¼ 0.046, P-trend ¼ 0.013) and haplotype analysis of PMS2 showed significant association in a global test (P 7df ¼ 0.005) with one rare haplotype (frequency 4%) accounting for most of the effect. PMS2 rs7797466 encodes a variant in intron 1 of the gene which is not in a conserved region (http://genome.ucsc.edu/cgi-bin/hgGateway) and is unlikely to have a direct functional effect. It is correlated with two other SNPs (r p 2 ¼ 0.7), both of which are intronic and unlikely to be functional. There are two rare coding SNPs in the gene, rs1805324 M622I (2.2%) and rs1805318 T597S (3.3%), but neither of these are correlated with rs7797466 (r p 2 < 0.1). The EGP is planning to resequence this gene at some time in the future. Such data may identify other putative functional variants tagged by the associated SNP/ haplotype. We also found weaker evidence of disease associations for the SNPs MSH6 rs3136245 and MSH3 rs6151662. Both variants are intronic and not located within conserved regions of either gene, so are unlikely to have any functional effect; but they may be linked to as yet unidentified functional variants.
These results need to be interpreted with some caution. First, the comparison of genotype frequencies in ovarian cases and controls were marginally significant for only one SNP (PMS2 rs7797466) out of 44 SNPs tested, and this result may have occurred by chance. The P-values presented above have not been adjusted for multiple hypothesis testing. Since SNPs within the same gene may be in linkage disequilibrium, the test statistics for the 44 SNPs are not independent, and standard methods for adjusting for multiple testing, such as the Bonferroni correction, would be too conservative. We therefore used a simulation to determine an empirical P-value for the most significant result. In this analysis, we randomly shuffled the case-control status among individuals multiple times, and estimated how frequently a P-value <0.013 was obtained for from the randomly permuted data. In 1000 permutations P < 0.013 was observed on 426 occasions, giving P-value corrected for multiple testing of 0.43. This suggests that the marginally significant results that we observed may be the result of chance. There are a very large number of candidate ovarian cancer susceptibility polymorphisms and the prior probability of association is very low. Consequently, some authors have suggested that stringent criteria should be applied to statistical tests for genetic association, e.g. P < 10 À4 or even P < 10 À7 (24) . A total of 7800 cases and an equal number of controls would be needed to detect a co-dominant allele with a minor allele frequency of 0.18 that confer a risk of 1.17 with 90% power and a Type I error rate of 10 À4 . Hidden population stratification is an alternative explanation for a spurious association. This occurs when allele frequencies differ between population subgroups and case and controls are drawn differentially from those subgroups. It seems unlikely that population stratification is relevant in this association study because the cases and controls in the three studies reported here were drawn from the same ethnic groups. Furthermore, if stratification were present, it is unlikely that the same degree of stratification would be seen in all three studies. It is also worth noting that the existence of significant population stratification that has resulted in a false genetic association has never been empirically demonstrated (25) . Finally, delay between diagnosis and recruitment into the studies may bias an association if a SNP is associated with prognosis. This is particularly relevant for the SEARCH study where a substantial proportion of potentially eligible cases had either died or permission to contact was refused. Nevertheless, there was no association between the time to blood draw after diagnosis for all but one of the SNPs (P > 0.04). For these SNPs, substantial survival bias is unlikely. MSH3 rs26279 was associated with time to blood draw (P ¼ 0.006), but this SNP was not associated with disease. We found no evidence for association for the other 41 SNPs tested here with invasive ovarian cancer. This study include a minimum of 1279 cases and 1897 controls providing us with at least 89% power at the 0.001 level of significance to detect a co-dominant allele with frequency 0.3 that confers a relative risk of 1.3 or 76% power to detect a dominant allele with frequency of 0.1 that confers a relative risk of 1.3 with a type I error rate of 0.05. However, we cannot exclude the possibility that the alleles investigated are associated with smaller risks. Alternatively, there may be other susceptibility variants in these genes that are not strongly correlated with the polymorphisms examined. The SNPs tested were chosen in order to efficiently tag all the common variants in the genes, but assay design failed for eight stSNPs (four in MSH6, two in PMS2 and one each in MLH1 and PMS1), and alternative stSNPs were either not available or also failed assay design. One of the failed stSNPs (PMS2 rs1059060) is a particularly good candidate because it encodes a non-synonymous amino acid change, Asn775Ser, that is situated in the PMS2-MLH1 interaction region (26) . Furthermore, the data on which our stSNP selection was based are incomplete-for the genes where resequencing data were available, only 30-84% of the gene had been resequenced, so SNPs in the non-sequenced regions may not be tagged. In addition, rarer SNPs may have been missed by chance because the resequencing sample size was small (we based the stSNP selection on 62 individuals). It is not known how well stSNPs selected using HapMap data tag all the common variants in a gene, but where the HapMap SNP density high it is likely that most of the common variation is captured. We used HapMap data to tag MSH3 but by the time the project was complete, EGP resequencing data were also available. Of the 201 common SNPs in the EGP data only 37 SNPs were also on HapMap, and just 4 of the 10 selected tag SNPs were identified in the EGP data. These 4 SNPs tagged 88 of the 201 with r 2 p > 0:8 and mean r 2 p of 0.55, but a much better performance would be expected for the full set of 10 stSNPs.
The absence of an association for common variants in MMR genes is not inconsistent with the fact that rare, deleterious mutation in these genes are associated with ovarian cancer as part of the HNPCC phenotype. Common variants in other high penetrance cancer susceptibility genes have been widely studied and none have emerged as definitive low-penetrance genes.
In conclusion, we have genotyped 44 SNP to tag the common variants in seven MMR genes in three studies. We found some evidence of association for PMS2 rs7797466 and for a rare PMS2 haplotype (global test P 7df ¼ 0.005). We found little evidence of association for the other six MMR genes. It is unlikely that common variants in MLH1, MLH3, MSH2, MSH3, MSH6 and PMS1 contribute significantly to ovarian susceptibility, although we cannot exclude completely the possibility that other as yet unidentified variants are important (e.g. SNPs in distant regulatory regions or SNPs on haplotypes not efficiently tagged by those stSNPs genotyped to date). The observed association of PMS2 rs7797466 with ovarian cancer risk warrants confirmation in an independent study and, if replicated, further investigation will be needed to identify the true functional variant.
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